ANI Pharmaceuticals ANIP Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Net Revenues by Business | |||||
| Generics and Other | $399.43M+24.8% | $320.03M+10.6% | $289.31M+23.0% | $235.24M— | |
| Rare Disease and Brands | $483.93M+64.4% | $294.34M+49.0% | $197.5M+143% | $81.15M— | |
| Other (expense)income , net by Business | |||||
| Generics and Other | $0— | $0— | $0— | $0— | |
| Rare Disease and Brands | $0— | $0— | $0— | $0— | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest by Business | |||||
| Generics and Other | $154.99M+33.6% | $116.02M+9.5% | $105.93M+23.9% | $85.48M— | |
| Rare Disease and Brands | $141.24M+94.9% | $72.47M-18.7% | $89.17M+746% | $10.54M— | |
| Operating Income (Loss) by Business | |||||
| Generics and Other | $154.99M+33.6% | $116.02M+9.5% | $105.93M+23.9% | $85.48M— | |
| Rare Disease and Brands | $141.24M+94.9% | $72.47M-18.7% | $89.17M+746% | $10.54M— | |
| Net Interest Expense by Business | |||||
| Generics and Other | $0— | $0— | $0— | $0— | |
| Rare Disease and Brands | $0— | $0— | $0— | $0— | |
| Cost of sales (excluding depreciation and amortization) by Business | |||||
| Generics and Other | $201.96M+19.9% | $168.37M+10.2% | $152.74M+21.4% | $125.84M— | |
| Rare Disease and Brands | $139.36M+70.3% | $81.84M+184% | $28.77M+122% | $12.95M— | |
| Selling, General and Administrative Expense by Business | |||||
| Generics and Other | $5.68M+10.8% | $5.12M+109% | $2.45M-38.2% | $3.96M— | |
| Rare Disease and Brands | $188.49M+49.6% | $125.97M+71.5% | $73.47M+32.8% | $55.31M— | |
| Unrealized gain (loss) on investment in equity securities by Business | |||||
| Generics and Other | $0— | $0— | —— | —— | |
| Rare Disease and Brands | $0— | $0— | —— | —— | |
| Research and Development expense by Business | |||||
| Generics and Other | $36.82M+20.6% | $30.52M+8.2% | $28.2M+41.2% | $19.96M— | |
| Rare Disease and Brands | $14.85M+5.6% | $14.06M+131% | $6.09M+159% | $2.35M— | |
| D&A by Business | |||||
| Generics and Other | $0— | $0— | $0— | $0— | |
| Rare Disease and Brands | $0— | $0— | $0— | $0— | |
| Contingent consideration fair value adjustment by Business | |||||
| Generics and Other | $0— | $0— | $0— | $0— | |
| Rare Disease and Brands | $0— | $0— | $0— | $0— | |
| Net Revenues by Product | |||||
| Brands | $61.31M-5.3% | $64.74M-24.2% | $85.38M+116% | $39.46M— | |
| Cortrophin Gel | $347.78M+75.6% | $198.09M— | —— | $41.69M— | |
| Generic pharmaceutical products | $384.11M+27.6% | $301M+11.7% | $269.45M+28.2% | $210.12M+46.0% | |
| ILUVIEN and YUTIQ | $74.87M+138% | $31.51M— | —— | $0— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does ANI Pharmaceuticals break its business down?
- ANI Pharmaceuticals (ANIP) reports net revenues by business across 2 parts — Generics and Other and Rare Disease and Brands. Each is extracted from the segment footnotes and tracked over time.
- Where does ANI Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in ANI Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
